Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|January 2, 2015
- Pharmaceutical Technology-01-02-2015
- Volume 39
- Issue 1
Shimadzu ICP Optical Emission Spectrometer Decreases Costs
Shimadzu’s ICPE-9800 series of simultaneous ICP optical emission spectrometers feature an eco mode to reduce operating costs by suppressing argon gas flow rate and power consumption by 50%. Used for analytical service and quality control laboratories, the series features two models: the ICPE-9810 with axial view plasma observation in a direction coaxial to the plasma, and ICPE-9820 with axial view and radial view plasma observation in the perpendicular direction.
The series is designed with Shimadzu’s vertically oriented mini-torch system to reduce argon gas consumption, power, memory effects, and rinse time. Even when using 99.95% pure argon gas, and not the typical gas of 99.99% or purer, the systems are able to ensure performance while reducing operating costs. ICPEsolution software allows users to save spectral data, add separate elements and wavelengths after measuring, and check or re-analyze data.
Shimadzu
Article DetailsPharmaceutical Technology
Vol. No. 1
Page: 14
Articles in this issue
over 11 years ago
Value-Based Healthcare in the: United Kingdomover 11 years ago
Mitigating Risk for Single-Use Assemblies in Sterile Fillingover 11 years ago
Building a Barrier in Solid-Dosage Drug Packagingover 11 years ago
Using Tocophersolan for Drug Deliveryover 11 years ago
Industry Expert Q&A with Fred Miesowiczover 11 years ago
Innovative Excipients in Solid-Dosage Manufacturingover 11 years ago
Great Expectations from New European Commissionover 11 years ago
Analyzing Protein Aggregation in Biopharmaceuticalsover 11 years ago
Ross Charging Hopper Increases Efficiencyover 11 years ago
Standards Organizations UpdateRelated to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.